4th Quarter - Report

ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

- International corporate tax reform; Puerto Rico tax incentives

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
ISRAEL S KLEIN —
VINCENT A. ROBERTI, SR. —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

- Issues related to Medicare Part B (Average Sales Price) and Part D (rebates)

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
ISRAEL S KLEIN —
VINCENT A. ROBERTI, SR. —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

- Issues relating to the 340B Drug Pricing Program - American Health Care Act (H.R. 1628) and Better Care Reconciliation Act - Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA) - Issues related to biosimilars, generally - Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771) - Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)

LobbyistCovered position, as disclosed
STEVEN E IRIZARRY —
ISRAEL S KLEIN —
VINCENT A. ROBERTI, SR. —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1245 (115th), H.R. 1628 (115th), S. 469 (115th), S. 771 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.